Key result
Targeted long-read RNA sequencing reveals ~46% improperly spliced reads in a rare MYBPC3 variant.
Why the study?
Clinical sequencing has traditionally focused on genomic DNA rather than investigating transcriptomic consequences of disease-associated variants, which RNA sequencing can effectively identify.
Case Report (n=10)
Targeted long-read RNA sequencing provides a valuable tool for identifying the transcriptomic consequences of rare splice-site variants in hypertrophic cardiomyopathy.
May refine splice variant interpretation in HCM; leaves open routine clinical adoption of long-read sequencing.
Background Clinical sequencing has traditionally focused on genomic DNA through the use of targeted panels and exome sequencing, rather than investigating the potential transcriptomic consequences of disease-associated variants. RNA sequencing has recently been shown to be an effective additional tool for identifying disease-causing variants. We here use targeted long-read genome and transcriptome sequencing to efficiently and economically identify molecular consequences of a rare, disease-associated variant in hypertrophic cardiomyopathy (HCM). Methods and Results Our study, which employed both Pacific Biosciences SMRT sequencing and Oxford Nanopore Technologies MinION sequencing, as well as two RNA targeting strategies, identified alternatively-spliced isoforms that resulted from a splice-site variant containing allele in HCM. These included a predicted in-frame exon-skipping event, as well as an abundance of additional isoforms with unexpected intron-inclusion, exon-extension, and pseudo-exon events. The use of long-read RNA sequencing allowed us to not only investigate full length alternatively-spliced transcripts but also to phase them back to the variant-containing allele. Conclusions We suggest that targeted, long-read RNA sequencing in conjunction with genome sequencing may provide additional molecular evidence of disease for rare or de novo variants in cardiovascular disease, as well as providing new information about the consequence of these variants on downstream RNA and protein expression.
No takes yet. Share an insight, caveat, or question.
Dainis et al. (2019) conducted a case report in Hypertrophic cardiomyopathy (n=10). MYBPC3 c.1898-1G>A splice-site variant vs. Wild-type MYBPC3 allele was evaluated on Identification of alternatively-spliced isoforms. Targeted long-read RNA sequencing of a rare MYBPC3 splice-site variant revealed diverse alternatively-spliced isoforms, with 46% of aligned reads showing improper splicing phased to the variant allele.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: